HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Consumer Reports Has 'Concerns' About Echinacea, Turmeric Supplements

Executive Summary

Nonprofit advocacy group says one third of echinacea and turmeric supplements it tested contained ingredients in amounts lower than labeled or elevated levels of lead or bacteria. Industry groups say CR used "arbitrary" standards based on preconceived, critical view of US supplement regulation.

You may also be interested in...



US FDA-Funded Study Spurs Consumer Reports’ Latest Lament On VMS Market Oversight

Abstract of study notes methylsynephrine and isopropyloctopamine found in bitter orange supplements aren’t permitted by FDA as dietary ingredients. CR says despite the findings, FDA hasn't enforced against manufacturers or warned consumers.

FDA Suggests Legislation To Streamline Enforcement In Supplement Market

Congress should consider legislation authorizing agency to conduct enforcement more directly, says Associate Commissioner Schiller. In FDLI conference keynote, he discussed compliance with FDA regulations across markets it regulates, but made specific example of saying FDA is comparatively hamstrung in regulating businesses marketing products labeled as supplements.

Modernizing FDA's Supplement Industry Regulation Mapped Out In Five-Point Plan

Commissioner Scott Gottlieb announces FDA's plan for policy changes to implement "one of the most significant modernizations of dietary supplement regulation and oversight in more than 25 years." Plan includes steps to ensure its regulatory framework is flexible enough to adequately evaluate product safety while also promoting innovation, particularly finalizing NDI notifications guidance and fostering submissions of the notifications.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1135947

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel